# A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

> **NCT02296983** · PHASE1 · UNKNOWN · sponsor: **University of Oxford** · enrollment: 40 (estimated)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **BIOLOGICAL:** VSV-ZEBOV

## Key facts

- **NCT ID:** NCT02296983
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296983, "A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02296983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*